Relative Bioavailability Study and Food Effect Study of TT-00420 (Tinengotinib) Capsule and Tablet Formulations in Healthy Volunteers
A Phase I, Single-Center, Open-Label, 3-Way Crossover, Randomized Single Dose Study to Evaluate the Food Effect on the Pharmacokinetics of TT-00420 Tablet and to Determine the Relative Bioavailability of TT-00420 Tablet Versus TT-00420 Capsule in Adult Healthy Volunteers
Sponsor: TransThera Sciences (Nanjing), Inc.
Listed as NCT04705922, this PHASE1 trial focuses on Healthy and remains completed. Sponsored by TransThera Sciences (Nanjing), Inc., it has been updated 8 times since 2020, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Feb 2024 — Jul 2024 [monthly]
Completed PHASE1
-
Oct 2021 — Feb 2024 [monthly]
Completed PHASE1
-
Sep 2021 — Oct 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
▶ Show 3 earlier versions
-
Jun 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE1
-
May 2021 — Jun 2021 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Feb 2021 — May 2021 [monthly]
Recruiting PHASE1
First recorded
Dec 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- TransThera Sciences (Nanjing), Inc.
For direct contact, visit the study record on ClinicalTrials.gov .